

## Supplemental Methods

*Stimulated Emission Depletion (STED) confocal microscopy.* ATTO-647N labeled Phalloidin (30 nM in 1% DMSO, Atto-tec, Siegen, Germany) was applied to plated DRGs for 10 min prior to being fixed, washed and mounted following specific guidelines for sample preparation (48). High-resolution images shown in SFig. 3 were obtained using a Leica TCS SP5 STED confocal system (Leica Microsystems, Wetzlar, Germany) equipped with an oil immersion objective (HCX PL APO CS 100x/1.40NA STED). A 635nm pulsed diode laser (PicoQuant, Germany) was used for excitation. The pulses for STED depletion were delivered using a tunable ultrafast Ti:Sapphire laser (Mai Tai® Broadband, Spectra-Physics, CA) emitting at a wavelength of 750 nm. Red fluorescence emitted from an ATTO 647N-labeled Phalloidin was collected through a Semrock BrightLine® 685/40-25 nm band pass filter (FF01-685/40-25, Semrock, Rochester, NY) in front of an avalanche photodiode (APD, PerkinElmer, Waltham, MA).

## Supplemental Figure Legends

**SFig. 1** *Ca<sup>2+</sup> channel density, type and constitutive  $\delta$ OR-VDCC coupling are not regulated by  $\beta$ -arr1- related to Figure 1.* A.i. A successive voltage step protocol was used to examine Ca<sup>2+</sup> current density. Examples of these recordings from early postnatal  $\beta$ -arr1<sup>-/-</sup> and  $+/+$  neurons are shown above the line graph, which in depicting the current-voltage relationship (ii), indicates no effect of  $\beta$ -arrestin 1 on Ca<sup>2+</sup> current density. B. The relative contribution of the N, P/Q and L-Ca<sup>2+</sup> channels to the Ca<sup>2+</sup> current was also examined by inhibiting each channel. i. After obtaining a stable basal Ca<sup>2+</sup> current (1),  $\omega$ -Conotoxin GVIA (10 $\mu$ M, 1% cytochrome C) was used to inhibit the N-type channel (2). ii. A similar protocol was used to inhibit the P/Q-type channels before (1) and during (2) the application of Agatoxin IVA (100nM). iii. The

contribution of the L-type channels was assessed by Nifedipine (3, 10 $\mu$ M, 0.1% DMSO) after a stable baseline was obtained (1) and the N-type was fully inhibited by  $\omega$ -Conotoxin GVIA (2). The resulting inhibition, expressed as a percent of the total Ca<sup>2+</sup> current, showed no effect of genotype on the relative contribution of the N (i) , P/Q (ii) or L-type (iii) Ca<sup>2+</sup> currents. C. Constitutive inhibition of the VDCCs was examined by a 2-step protocol. Examples of this protocol, which uses a high voltage pre-pulse to dissociate constitutively coupled G $\beta\gamma$  subunits from Ca<sup>2+</sup> channels are shown (i), 1 indicates the current measured without a pre-pulse (P1) and 2 (P2) that recorded after the pre-pulse is applied. The P2/P1 ratio, reflecting constitutive Ca<sup>2+</sup> channel coupling, was increased in the large, but not small DRG neurons. This ratio was further enhanced in  $\beta$ -arr1<sup>-/-</sup> neurons. ii. However, ICI 174.864, a  $\delta$ OR inverse agonist, could not reverse the enhanced effect in the  $\beta$ -arr1<sup>-/-</sup> neurons suggesting that although there is evidence of enhanced constitutive coupling of G $\beta\gamma$  subunits with VDCCs, this is not mediated by  $\delta$ ORs. All pooled data are shown as mean $\pm$ SEM.

**SFig. 2** *Flow Cytometry assessment of  $\delta$ OR antibody specificity- related to Figure 2.* DRG neurons from  $\delta$ OR <sup>+/+</sup> and <sup>-/-</sup> early postnatal mice were cultured for 48h, re-suspended and labeled with an antibody to the N-terminus of the human  $\delta$ OR sequence (MBL) followed by an APC-conjugated secondary and analyzed by flow cytometry. Unlabeled  $\delta$ OR<sup>+/+</sup> neurons that had not been incubated with either antibody were included. Using the same template as shown in Fig. 2Ci to select medium-large sized neurons, scatterplots of the fluorescence intensity of the unlabeled and labeled  $\delta$ OR<sup>-/-</sup> and <sup>+/+</sup> neurons are shown (1 dot=1 cell). These plots show no

difference in labeling between the unlabeled and  $\delta$ OR  $-/-$  samples whereas the  $\delta$ OR  $+/+$  sample shows a greater percentage of APC or  $\delta$ OR-positive cells.


**SFig. 3** *SNC80 internalizes cerulean-tagged  $\delta$ ORs in both  $\beta$ -arr1 $+/+$  and  $-/-$  DRG neurons- related to Figure 2.* After 1h of SNC80 (1 $\mu$ M), virally expressed cerulean-tagged  $\delta$ ORs, demonstrate equivalent internalization, when imaged by epifluorescence, in cultured  $\beta$ -arr1 $+/+$  and  $-/-$  DRG neurons. The cell bodies and processes from untreated DRGs are shown in a and b respectively whereas c and d show the cell bodies and processes from SNC80-treated DRG neurons. The top and bottom rows are of  $\beta$ -arr1 $+/+$  and  $-/-$  neurons. Scale-bar=10 $\mu$ m. Images were acquired on a Nikon TE2000 using a 60x objective and imaged by a Retiga1300 CCD and Iplab v4 (Qimaging, Ontario, CA).

**SFig. 4** *Basal F-actin incorporation is not altered in  $\beta$ -arr1 $-/-$  neurons- related to Figure 4.*  $\beta$ -arr1 $+/+$  and  $-/-$  neurons were incubated with Phalloidin-Atto647N for 10 min at 37°C, fixed and imaged by STED microscopy. There was no apparent effect of genotype on Phalloidin incorporation in the cell bodies and processes of  $\beta$ -arr1 $+/+$  (a and b respectively) and  $-/-$  (c and d respectively) neurons. Scale-bar=2 $\mu$ m.


**SFig. 5** *The behavioral effects of a delta agonist are similarly enhanced in  $\beta$ -arr1 $-/-$  and  $+/+$  mice in the C57BL/6 background- related to Figure 5.* A. Fentanyl produced a hyperlocomotor response in  $\beta$ -arr1 $+/+$  ( $p < 0.05$ ,  $F_{2,21} = 5.03$  locomotion x treatment) and in  $\beta$ -arr1 $-/-$  mice ( $p < 0.01$ ,  $F_{2,23} = 7.80$  locomotion x treatment), which was unaffected by pretreatment with the ROCK inhibitor, Y27632. Furthermore, no differences were observed in fentanyl-induced locomotion

between the two genotypes ( $p=0.92$ ,  $F_{1,10}=0.01$ ),  $*p<0.05$  vs. other treatment groups. B. SNC80 (1mg/kg s.c.) produced a hyperlocomotor response in  $\beta$ -arr1 $^{+/+}$  ( $p<0.05$ ,  $F_{1,17}=6.31$  vs. vehicle),  $\beta$ -arr1 $^{-/-}$  ( $p<0.001$ ,  $F_{1,19}=78.13$  vs. vehicle),  $\beta$ -arr2 $^{+/+}$  ( $p<0.01$ ,  $F_{1,18}=9.62$  vs. vehicle), as well as,  $\beta$ -arr2 $^{-/-}$  ( $p<0.05$ ,  $F_{1,17}=7.85$  vs. vehicle) in the C57Bl/6 background. However, this effect was enhanced in  $\beta$ -arr1 $^{-/-}$  mice as compared to the other three groups ( $p<0.05$ ,  $F_{3,33}=4.255$  locomotion x genotype)  $**p<0.01$ ,  $*p<0.05$  vs. other groups receiving the same treatment. C. The Von-Frey test for mechanical allodynia was used to measure sensitivity to mechanical pain on the plantar surface of the right paw after vehicle or SNC80 (5 mg/kg s.c.). While both groups showed similar basal responses ( $p=0.98$ ), and SNC80 had no effect in  $\beta$ -arr1 $^{+/+}$  mice,  $\beta$ -arr1 $^{-/-}$  mice responded less than  $+/+$  mice 20 and 40 min after the SNC80 injection ( $p<0.001$ ,  $F_{1,27}=53.41$  vs.  $\beta$ -arr1 $^{+/+}$ ). All data are shown as mean $\pm$ SEM.

SFig. 1




SFig. 2




SFig 3


$\beta$ -arr1<sup>+/+</sup>



$\beta$ -arr1<sup>-/-</sup>




SFig. 4






SFig. 5

A



B



C

